证券代码：002758 证券简称：浙农股份 债券代码：128040 债券简称：华通转债 浙农集团股份有限公司投资者关系活动记录表 编号：2022-05 | --- | --- | --- | --- | --- | |-------------------------|----------------------------------|-----------|----------------------------------------------------------|-------| | | | | | | | | 特定对象调研 □分析师会议 | | | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | | 类别 | □新闻发布会 | □路演活动 | | | | | 现场参观 | | | | | | □其他 | | （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 深圳市杉树资产管理有限公司：袁斌 | | | | | 时间 2022 | 年 7 月 14 日 | | 15:00-16:00 | | | | 地点 公司会议室 | | | | | 上市公司接待人 ...

证券代码：002758 证券简称：浙农股份 债券代码：128040 债券简称：华通转债 浙农集团股份有限公司投资者关系活动记录表 编号：2022-11 | --- | --- | --- | --- | |-----------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------| | | 特定对象调研 | □ 分析师会议 | | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | | 类别 | □ 新闻发布会 □ | 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | | 德邦证券：林浩睿； ...

证券代码：002758 证券简称：浙农股份 债券代码：128040 债券简称：华通转债 编号：2022-07 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|------------------------------|--------------------------------------------|-------|-------|---------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | 特定对象调研 □分析师会议 | | | | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | | | | 类别 | □新闻发布会 现场参观 | □路演活动 | | | | | | | | | | | | | | | □其他 | （请文字说明其他活动内容） | | | | | | 参与单 ...

证券代码：002758 证券简称：浙农股份 债券代码：128040 债券简称：华通转债 浙农集团股份有限公司投资者关系活动记录表 编号：2022-09 | --- | --- | --- | --- | --- | |-------------------------|-------------------------------------------------------------|--------------------------------------------------------|--------|------------| | 投资者关系活动 \n类别 | 特定对象调研 \n□ 媒体采访 □ \n□ 新闻发布会 □ \n□ 现场参观 | □ 分析师会议 \n业绩说明会 \n路演活动 | | | | | □ 其他 | （请文字说明其他活动内容） | | | | 参与单位名称及 人员姓名 | | 永赢基金：晏青、张海啸、安慧丽；长江证券：顾熀乾 | | | | 时间 | 2022 年 11 月 2 日 | 15:00-16:00 | | | | 地点 | 公司会议室和线上交流 | | | ...

Financial Performance - The company's revenue for the third quarter reached ¥11,240,860,776.07, an increase of 26.44% compared to the same period last year[3] - Net profit attributable to shareholders decreased by 20.40% to ¥143,376,063.09 for the third quarter[3] - The net profit after deducting non-recurring gains and losses was ¥126,767,802.42, down 25.36% year-on-year[3] - Basic earnings per share for the third quarter were ¥0.29, a decrease of 21.62% compared to the previous year[4] - Total operating revenue for the current period reached ¥30,852,367,108.46, an increase of 16.5% compared to ¥26,550,994,886.35 in the previous period[23] - Net profit for the current period was ¥838,431,904.55, representing an increase of 6.1% from ¥790,642,314.01 in the previous period[25] - Net income attributable to the parent company was ¥401,568,580.92, down from ¥439,602,444.08 year-over-year[26] - Total comprehensive income amounted to ¥834,476,416.05, a slight decrease from ¥840,307,226.87 in the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥18,522,719,957.35, reflecting a growth of 13.55% from the end of the previous year[4] - The total assets increased to ¥18,522,719,957.35, compared to ¥16,312,540,728.50, marking a growth of 13.5%[22] - Total liabilities rose to ¥12,303,450,526.63, up from ¥10,401,824,130.33, indicating a growth of 18.3%[22] - The equity attributable to shareholders of the parent company increased to ¥3,885,589,833.16, compared to ¥3,586,023,134.39, reflecting a growth of 8.3%[22] - The company reported a significant increase in short-term borrowings, which rose to ¥2,546,082,389.75 from ¥1,869,904,310.42, an increase of 36.1%[22] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥1,785,395,510.55, a significant increase of 169.82%[3] - Cash flow from operating activities generated a net cash inflow of ¥1,785,395,510.55, significantly up from ¥661,708,552.50 in the prior period[27] - Cash inflow from investment activities was ¥1,661,173,897.55, compared to ¥1,462,078,097.33 in the previous year[27] - Net cash flow from financing activities was negative at -¥857,686,322.43, worsening from -¥124,195,044.97 year-over-year[27] - The ending balance of cash and cash equivalents increased to ¥3,595,706,005.15 from ¥1,979,290,261.11[27] - The company received cash from investment totaling ¥179,904,040.48, up from ¥79,206,900.00 in the previous period[27] - Cash received from borrowings was ¥3,059,947,937.77, compared to ¥1,761,445,484.66 in the prior year[27] Business Development - The company launched the "Zhe Nong Yun" agricultural service brand, focusing on modern agricultural socialized service systems[8] - The company expanded its traditional Chinese medicine business, adding approximately 100 new cooperative medical institutions in the first three quarters of 2022[8] - The company launched its first modern agricultural social service brand "Zhe Nong Yun" in August 2022, aiming to create a comprehensive service ecosystem from soil to table[15] - The company is actively exploring new agricultural service models, including soil remediation and the establishment of modern agricultural demonstration zones[16] - The company established Zhe Nong Modern Agriculture Co., Ltd. to build a comprehensive agricultural social service system, with service centers launched in August 2022[14] - The company is developing a full industry chain model for traditional Chinese medicine, focusing on standardized planting and quality traceability[19] - The company signed strategic cooperation agreements for land transfer and modern agricultural park construction in April and June 2022, enhancing its service capabilities[16] Inventory and Current Assets - The company's inventory increased to CNY 5.25 billion from CNY 4.92 billion, reflecting a growth of approximately 6.7%[20] - The total current assets rose to CNY 14.68 billion, up from CNY 12.58 billion, indicating an increase of about 16.7%[20]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥19.61 billion, representing an increase of 11.05% compared to ¥17.66 billion in the same period last year[22]. - The net profit attributable to shareholders of the listed company reached approximately ¥266.47 million, a year-on-year increase of 27.11% from ¥209.64 million[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥242.37 million, up 31.47% from ¥184.36 million in the previous year[22]. - The net cash flow from operating activities was approximately ¥712.83 million, reflecting a significant increase of 56.90% compared to ¥454.33 million in the same period last year[22]. - Basic earnings per share increased to ¥0.54, up 25.58% from ¥0.43 in the previous year[22]. - Total assets at the end of the reporting period were approximately ¥19.30 billion, an increase of 18.34% from ¥16.31 billion at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were approximately ¥3.75 billion, a 4.48% increase from ¥3.59 billion at the end of the previous year[22]. Revenue Breakdown - Agricultural comprehensive services accounted for 57.13% of total revenue, generating 11.203 billion yuan[30]. - The automotive trading service generated 7.496 billion yuan, making up 38.22% of total revenue[30]. - The pharmaceutical production and sales segment contributed 912 million yuan, representing 4.65% of total revenue[30]. - The revenue from agricultural comprehensive services was ¥11.20 billion, accounting for 57.13% of total revenue, with a year-on-year growth of 45.85%[59]. - The revenue from fertilizer products increased by 62.91% to ¥9.01 billion, driven by significant price increases in urea, potassium fertilizer, and compound fertilizer[61]. Strategic Initiatives - The company is actively expanding its agricultural service network, establishing regional companies in Beijing, Shanxi, and Shandong[31]. - The company is enhancing its agricultural service capabilities through strategic partnerships and modern agricultural service models[31][35]. - The automotive service segment is implementing various promotional activities to boost sales amid a challenging market environment[32]. - The pharmaceutical segment is focusing on collaboration with drug companies and expanding its retail network, with 520 medical institutions engaged in its services[33]. - The company has established 32 standardized 4S stores across Zhejiang and Jiangsu provinces, obtaining regional dealership rights for brands such as BMW, MINI, Audi, and Cadillac[36]. Market Challenges - The company faces various risks including market competition and changes in customer demand, which are detailed in the risk management section of the report[4]. - The company is exposed to risks related to product quality and brand reputation, as it relies on upstream manufacturers whose quality standards may vary[95]. - Price volatility in agricultural and automotive products is influenced by national policies, raw material prices, and market supply-demand dynamics, which the company is actively managing through diversified operations[95]. - The company acknowledges the possibility of adverse impacts from uncontrollable factors such as political, economic, and natural disasters[98]. Future Outlook - The company aims to achieve full intelligence in key areas by 2025, with the automotive aftermarket and service industry expected to account for over 55% of the value chain[44]. - The company plans to complete the investment projects funded by the convertible bonds by December 31, 2023[82]. - Future guidance indicates a strong commitment to sustainability, with plans to reduce operational costs by 97.87% through innovative practices[154]. - The company is exploring potential mergers and acquisitions to enhance its product offerings and market presence, with a budget of 40,000 million earmarked for strategic investments[141]. Corporate Governance - The company emphasizes the protection of shareholder rights and has implemented a structured governance framework to ensure transparency and fairness[110]. - The company has retained an employee stock ownership model, fostering a strong connection between employee interests and company performance[53]. - The company has not faced any significant environmental penalties during the reporting period[109]. Investment and Financing - The company aims to enhance its financing channels and has initiated supply chain finance trials in collaboration with major banks[56]. - The total amount raised from the initial public offering was RMB 252.56 million, with a net amount of RMB 220.98 million after deducting related expenses[78]. - The company has established strict internal control procedures for the approval and use of funds in foreign exchange and commodity futures hedging activities[74]. User Engagement and Market Expansion - User data indicated a growth of 3,280 million in the second quarter of 2022, reflecting a strong demand for the company's products[140]. - The company is planning market expansion with a target of reaching 17,000 million in new user acquisitions by the end of 2022[140]. - The company is focusing on enhancing its supply chain efficiency, with an investment of 3,000 million planned for infrastructure improvements[140]. Risk Management - The company identified market risk, credit risk, operational risk, and legal risk as potential risks associated with its hedging activities[73]. - The company has established a risk control system for foreign exchange hedging, focusing on monitoring international foreign exchange market dynamics and adjusting strategies to minimize exchange losses[74]. Environmental and Social Responsibility - The company emphasizes environmental protection and sustainable development, integrating these principles into daily operations[113]. - The company has actively participated in pandemic response efforts, including the establishment of nucleic acid sampling points and the donation of medical supplies[114].

证券代码：002758 证券简称：浙农股份 公告编号：2022-047 号 债券代码：128040 债券简称：华通转债 浙农集团股份有限公司 关于参加 2022 年浙江辖区上市公司投资者网上集体接待日活动 暨举办 2021 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，提升公司投资者关系管理水平，公司将 于 2022 年 5 月 13 日（星期五）15:00-17:00 参加 2022 年浙江辖区上市公司投 资者网上集体接待日活动暨举办 2021 年度业绩说明会，投资者朋友可登陆全景 网"投资者关系互动平台"（https://ir.p5w.net）参与本次交流。届时，公司 董事长包中海先生、总经理林昌斌先生、副总经理兼财务总监刘文琪先生、副总 经理兼董事会秘书金鼎先生、独立董事郭德贵先生，将通过互动平台与投资者进 行网络沟通和交流，欢迎广大投资者参加。 为提高互动交流的效率，现提前向所有关心公司的投资者公开征集交流问题， 广泛听取投资者的意见和建议。投资者可于 2022 年 5 月 12 日（星期四）17 ...

Financial Performance - The company reported a revenue of ¥9,469,580,257.41 for Q1 2022, representing a 17.12% increase compared to ¥8,085,650,242.98 in the same period last year[2] - Net profit attributable to shareholders reached ¥139,944,505.03, a significant increase of 74.15% from ¥80,356,828.57 year-on-year[2] - Basic earnings per share increased by 81.25% to ¥0.29 from ¥0.16 in the same period last year[2] - The total operating revenue for the period reached ¥9,469,580,257.41, an increase of 17.1% compared to ¥8,085,650,242.98 in the previous period[18] - The net profit attributable to the parent company was ¥2,445,993,849.85, reflecting an increase from ¥2,306,049,344.82 in the previous year[16] - The net profit for the current period was ¥276,594,305.15, compared to ¥165,871,366.26 in the previous period, indicating a year-over-year increase of about 66.7%[20] - The total profit before tax was ¥355,787,122.89, compared to ¥213,703,511.18 in the previous period, reflecting an increase of about 66.3%[20] - The company reported a total comprehensive income of ¥263,435,907.83, up from ¥176,679,815.99, marking an increase of approximately 49%[20] Cash Flow and Assets - The net cash flow from operating activities surged to ¥1,321,774,181.34, marking a remarkable growth of 718.66% compared to ¥161,456,390.51 in the previous year[2] - Cash and cash equivalents increased to ¥5,068,166,076.50 from ¥3,407,537,257.29, representing a growth of 48.8%[14] - Cash and cash equivalents at the end of the period totaled ¥3,580,373,108.01, compared to ¥2,085,861,101.71 at the end of the previous period, an increase of about 71.7%[23] - The company generated ¥653,725,681.88 in cash inflows from investing activities, compared to ¥625,758,498.71 in the previous period, showing a slight increase[22] - The net cash flow from financing activities was ¥121,689,859.62, down from ¥219,078,443.58 in the previous period, indicating a decrease of approximately 44.4%[22] - Total assets at the end of the reporting period amounted to ¥17,943,532,367.28, reflecting a 10.00% increase from ¥16,312,540,728.50 at the end of the previous year[2] - Total assets reached ¥17,943,532,367.28, up from ¥16,312,540,728.50, indicating a growth of 9.9%[15] Operational Highlights - The company attributed its strong performance to strategic planning, enhanced operational capabilities, and effective market response, particularly in the agricultural services sector[7] - The prices of key products such as urea, potassium fertilizer, and compound fertilizer saw significant increases due to rising commodity prices[7] - The company is actively expanding its traditional Chinese medicine business in response to national revitalization strategies, enhancing operational quality[7] Liabilities and Shareholder Information - The total liabilities increased to ¥11,734,044,413.75 from ¥10,401,824,130.33, reflecting a rise of 12.8%[16] - The company reported a total of 38,856 ordinary shareholders at the end of the reporting period[10] - Short-term borrowings increased to ¥2,155,692,175.91 from ¥1,869,904,310.42, an increase of 15.3%[16] - Accounts receivable rose to ¥811,020,202.29, up 27.3% from ¥636,855,009.84 at the beginning of the year[14] - Inventory decreased to ¥4,734,729,321.39 from ¥4,922,877,315.63, a decline of 3.8%[15] Stock and Equity - The weighted average return on equity improved to 3.82%, up from 2.67% in the previous year[2] - The company granted 12,515,000 restricted stocks to 446 incentive objects at a grant price of ¥5.37 per share[12]

Financial Performance - The company's operating revenue for 2021 was ¥35,143,834,632.84, representing a 22.25% increase compared to ¥28,747,252,789.39 in 2020[25]. - The net profit attributable to shareholders for 2021 was ¥658,384,303.75, an increase of 87.52% from ¥351,110,025.28 in 2020[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥596,751,972.27, a significant increase of 1,259.42% compared to ¥43,897,430.43 in 2020[25]. - The company's total assets at the end of 2021 were ¥16,312,540,728.50, a 29.68% increase from ¥12,579,456,290.43 at the end of 2020[25]. - The basic earnings per share for 2021 was ¥1.35, up 87.50% from ¥0.72 in 2020[25]. - The weighted average return on equity for 2021 was 20.12%, an increase of 7.57% compared to 12.55% in 2020[25]. - The total revenue for 2021 reached 1,635,469.71 million CNY, with a year-on-year increase of 13.87% in revenue from outside Zhejiang Province[47]. - The company reported a comparable operating income of 146,662.46 million CNY in 2021, up from 134,630.56 million CNY in 2020[47]. - The company reported a total of ¥61,632,331.48 in non-recurring gains for 2021, compared to ¥307,212,594.85 in 2020[31]. Dividends and Profit Distribution - The company reported a cash dividend of 3.00 RMB per 10 shares (including tax) to all shareholders, with no bonus shares or capital reserve conversion[5]. - The total distributable profit for the company as of December 31, 2021, is RMB 269,441,224.59, with a net profit of RMB 293,861,269.54 for the year[187]. - The cash dividend distribution accounts for 100% of the total profit distribution amount[187]. - The cash dividend distribution plan is subject to approval at the annual general meeting[187]. Corporate Governance - The board of directors confirmed the accuracy and completeness of the annual report, ensuring no false records or misleading statements[4]. - The company ensures compliance with corporate governance regulations, maintaining a transparent and independent operational structure[144]. - The company has established a complete independent business system, ensuring no asset or financial intermingling with the controlling shareholder[146]. - The company has developed a series of internal control systems to ensure compliance with regulatory requirements and effective risk management[145]. - The company maintains an independent financial accounting department, ensuring no interference from shareholders in financial decisions[147]. - The company has a complete organizational structure that operates independently from its controlling shareholder[148]. - The company has established a governance structure that includes a board of directors and various committees to enhance decision-making processes[200]. Market and Industry Position - The company has maintained a strong competitive position in the agricultural input distribution sector, ranking among the top three for 12 consecutive years according to the China Agricultural Production Materials Circulation Association[35]. - The company has established strategic partnerships with major domestic and international fertilizer manufacturers to enhance its supply chain capabilities[40]. - The company has engaged in continuous supervision and financial advisory services from Huajin Securities and Haitong Securities, respectively, since June 2020[23]. - The company has established strategic partnerships with top international agricultural production and trade companies, enhancing its resource advantages[52]. - The company is focused on expanding its market presence and enhancing product quality to mitigate identified risks[5]. Risks and Challenges - The company highlighted risks including market competition, changes in customer demand, and operational product quality, which are detailed in the management discussion section[5]. - The company acknowledges potential risks from changes in industrial policies that may impact its main products, including agricultural chemicals and automotive regulations[136]. - The company faces intensified market competition, with industry leaders increasing mergers to expand market share amid a fragmented market[136]. - The company recognizes the risk of changing customer demands, shifting from quantity to quality, particularly in agricultural inputs and pharmaceuticals[137]. - The company is aware of the risks associated with product quality and brand reputation, which could adversely affect downstream distributors[137]. Strategic Initiatives - The company is expanding its third-party pharmaceutical logistics and traditional Chinese medicine production, aiming for a comprehensive development model[41]. - The company plans to enhance its product offerings, including slow-release fertilizers and traditional Chinese medicine, to boost sales revenue[79]. - The company aims to enhance operational quality and accelerate new product development, optimizing product structure based on customer needs to increase market share and profitability[126]. - The company plans to strengthen mergers and acquisitions, leveraging its financing advantages to improve industry layout and enhance market value management[127]. - The company intends to improve service quality by building a modern agricultural social service system characterized by integration and digitalization[129]. Employee and Management - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 753.61 million[171]. - Chairman Bao Zhonghai received a total remuneration of CNY 67.75 million for the reporting period[170]. - General Manager Lin Changbin's remuneration was CNY 146.26 million, the highest among the directors[170]. - The company has a total of 32 stores, with 28 located in Zhejiang Province and 4 outside, covering a total area of 269,083.42 square meters[47]. - The company has implemented a talent inheritance mechanism to strengthen its human resources and enhance its market adaptability[54]. Research and Development - Research and development expenses increased by 7.78% to ¥13,546,859.08, with a significant increase in R&D personnel by 140% to 60[79]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficiency and sustainability[159]. - The company has established the Zhejiang Agricultural Modern Agricultural Technology Research Institute to focus on crop solutions and precision agriculture, utilizing technologies like AI and big data[54]. Operational Efficiency - The company has implemented cost-cutting measures that are projected to save approximately 50 million RMB annually[159]. - The company aims to reduce operational costs by 8% through efficiency improvements in the supply chain[165]. - The company has taken steps to improve its internal control processes, including the establishment of anti-fraud procedures and control measures[193]. Future Outlook - The company provided a revenue guidance of 1.5 billion RMB for the fiscal year 2022, indicating a projected growth of 25%[159]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a focus on companies in the health sector[159]. - The company plans to strengthen its pharmaceutical business by focusing on product channels and expanding direct chain stores in rural areas[130].

Financial Performance - The company's operating revenue for the third quarter reached 889,040,243.29 CNY, representing a 16.04% increase compared to the same period last year[3]. - The net profit attributable to shareholders was 180,112,603.33 CNY, marking a 19.96% increase year-over-year[3]. - The net profit after deducting non-recurring gains and losses was 169,841,175.48 CNY, which is a significant increase of 1,312.50% compared to the previous year[10]. - The basic earnings per share for the year-to-date period was 0.80 CNY, up 56.86% from the same period last year[4]. - The diluted earnings per share for the year-to-date period was 0.78 CNY, reflecting a 52.94% increase year-over-year[4]. - Total operating revenue for the period reached ¥26,550,994,886.35, an increase of 27.5% compared to ¥20,868,747,238.49 in the previous period[23]. - Net profit attributable to the parent company was ¥389,752,453.94, up 56.1% from ¥249,726,564.23 in the same period last year[25]. - The total comprehensive income for the period was ¥840,307,226.87, up from ¥485,800,222.77, indicating a growth of 73.1%[26]. Assets and Liabilities - The total assets at the end of the reporting period were 13,946,310,002.25 CNY, an increase of 10.87% compared to the end of the previous year[4]. - The company's total assets reached ¥13,946,310,002.25, up from ¥12,579,456,290.43, indicating a growth of 10.9%[22]. - The total liabilities increased to ¥8,638,997,010.47, compared to ¥7,594,031,896.57 in the previous period, reflecting a growth of 13.8%[22]. - The total cash outflow from operating activities amounted to CNY 29,588,842,162.29, up from CNY 22,514,899,220.96, indicating a 31.5% increase[29]. - Total liabilities amounted to CNY 7,594,031,896.57, with current liabilities at CNY 7,158,270,081.43[34]. - Non-current liabilities totaled CNY 435,761,815.14, including long-term borrowings of CNY 50,000,000.00 and bonds payable of CNY 195,954,907.21[34]. - The total equity attributable to shareholders of the parent company was ¥3,309,560,064.39, an increase of 11.8% from ¥2,959,365,599.32 in the previous period[22]. Cash Flow - The net cash flow from operating activities was 661,708,552.50 CNY, a decrease of 47.48% compared to the same period last year[10]. - Cash inflow from operating activities was ¥30,250,550,714.79, compared to ¥23,774,780,543.96 in the previous period, representing an increase of 27.5%[28]. - The net cash flow from investing activities was negative at CNY -15,191,740.69, compared to CNY -201,104,539.56 in the previous period, showing an improvement[29]. - Cash inflow from financing activities totaled CNY 2,111,033,498.68, an increase from CNY 1,679,893,605.05, reflecting a growth of 25.7%[30]. - The ending balance of cash and cash equivalents was CNY 1,979,290,261.11, up from CNY 1,454,846,918.43, representing a 36% increase[30]. Investments and Strategic Initiatives - The company plans to invest up to RMB 140 million in establishing a new BMW 4S dealership in Suzhou to enhance its sales network in Jiangsu Province[14]. - A new pharmaceutical sales subsidiary, Zhejiang Jingyuetang Pharmaceutical Co., Ltd., was established with a registered capital of RMB 100 million, where Zhejiang Huadong Pharmaceutical Group holds a 70% stake[15]. - The company signed a strategic cooperation agreement with Beijing Yingtai Jiahe Biotechnology Co., Ltd. to jointly develop specialized agricultural products, enhancing market share and resource sharing[17]. - Zhejiang Nong Group acquired 40 million shares of Yingtai Biotechnology at a price of RMB 5.3 per share, totaling RMB 21.2 million, increasing its stake to 3.26%[17]. - The establishment of Zhejiang Nong Modern Agriculture Co., Ltd. aims to integrate service resources and promote a comprehensive agricultural service system, with a registered capital of RMB 10 million[16]. Operational Highlights - The company reported a significant increase in the prices of agricultural products, benefiting from favorable market conditions[9]. - The company has seen a robust demand in the luxury car market, driven by government policies promoting consumption[9]. - The company is focused on enhancing its operational capabilities to achieve substantial growth in performance for the year[9]. Other Financial Information - The report for the third quarter was not audited, indicating preliminary financial data[36]. - The company has implemented new leasing standards starting in 2021, affecting financial reporting[36]. - The total amount of employee compensation payable was CNY 271,211,819.17, reflecting the company's commitment to its workforce[34]. - Tax liabilities amounted to CNY 223,686,337.10, indicating the company's tax obligations for the period[34]. - The company holds other payables totaling CNY 332,187,542.17, which may include various operational liabilities[34]. - The report was released on October 27, 2021, by the legal representative Bao Zhonghai[37].